These findings provide a novel pharmacological strategy (MPG-peptide) for inhibiting HIF1α expression, and which may be an effective therapeutic method for colorectal cancer treatment, mainly for anti-angiogenesis resistance patients. This evidence concerns the gene HIF1A and colorectal cancer.